Given that the characteristic ASPSCR1-TFE3 fusion gene drives aberrant activation of signaling pathways such as MET and vascular endothelial growth factor (VEGF), tyrosine kinase inhibitors (TKIs) targeting these pathways, including anlotinib and cabozantinib, have been applied in the management of ASPS. Here, ASPSCR1 is linked to alveolar soft part sarcoma.